X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer.
Lead Product(s): SY-5609,Fulvestrant
Therapeutic Area: Oncology Product Name: SY-5609
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
CDK12 inhibitor demonstrates strong anti-tumor activity as single agent and in combination with a DNA damaging agent and a PARP inhibitor in models of breast, lung, and ovarian cancer.
Lead Product(s): SY-5609,Olaparib,Lurbinectedin
Therapeutic Area: Oncology Product Name: SY-5609
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
The oral presentation will include safety, tolerability, and initial clinical activity data for SY-5609 in patients with breast, colorectal, lung, ovarian and pancreatic cancers, as well as in patients with solid tumors of any histology harboring Rb pathway alterations.
Lead Product(s): SY-5609
Therapeutic Area: Oncology Product Name: SY-5609
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2021
Details:
Syros will supply SY-5609 for a combination dosing cohort in Roche’s ongoing Phase 1/1b INTRINSIC trial, evaluating multiple targeted therapies or immunotherapy, including atezolizumab, as single agents or in rational specified combinations in colorectal cancer patients.
Lead Product(s): Atezolizumab,SY-5609
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 05, 2021
Details:
Early dose-escalation data demonstrate proof of mechanism and support ongoing development of SY-5609 for difficult-to-treat cancers .
Lead Product(s): SY-5609
Therapeutic Area: Oncology Product Name: SY-5609
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2020
Details:
Syros will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. yros will also present on the design of its ongoing Phase 1 trial of SY-5609 at ASCO20.
Lead Product(s): SY-5609
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The data show that SY-5609 inhibits tumor growth, including inducing sustained regressions, at well-tolerated doses in colorectal cancer models, supporting the inclusion of colorectal cancer patients in Syros’ ongoing Phase 1 clinical trial.
Lead Product(s): SY-5609
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
SY-5609 has shown substantial anti-tumor activity, including complete regressions, in multiple preclinical models of solid tumors, at doses below the maximum tolerated dose (MTD).
Lead Product(s): SY-5609,Fulvestrant
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
